Últimas noticias sobre Kezar Life Sciences (NASDAQ:KZR) Bolsa

KEZAR LIFE SCIENCES INC

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) has outperformed the market over the past 10 years by 13.4% on an annualized basis producing an average annual return of 23.68%. Currently, Ares Management has a market capitalization of $36.04 billion. 
Buying $100 In ARES: If an investor had bought $100 of ARES stock 10 years ago, it would be worth $855.99 today based on a price of $164.95 for ARES at the time of writing.
<h3>Ares Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746821718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ARES

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Biglari Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>) reported quarterly losses of $(126.40) per share. This is a 258.87 percent decrease over earnings of $79.56 per share from the same period last year. The company reported $95.03 million in sales this quarter. This is a 6.24 percent increase over sales of $89.45 million the same period last year.

Earnings

Biglari Holdings Q1 EPS $(126.40) Down From $79.56 YoY, Sales $95.03M Up From $89.45M YoY

Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) reported quarterly earnings of $0.33 per share. This is a 155 percent increase over losses of $(0.60) per share from the same period last year. The company reported $1.76 million in sales this quarter. This is a 41.96 percent decrease over sales of $3.03 million the same period last year.

MSGM

Motorsport Games Q1 EPS $0.33 Up From $(0.60) YoY, Sales $1.76M Down From $3.03M YoY

CIBC analyst Cosmos Chiu maintains Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) with a Outperformer and raises the price target from $95 to $105.

Price Target

Analyst Ratings

CIBC Maintains Outperformer on Wheaton Precious Metals, Raises Price Target to $105

NI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NODK#NASDAQ">NODK</a>) reported quarterly earnings of $0.31 per share. This is a 3.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported $71.43 million in sales this quarter. This is a 4.11 percent decrease over sales of $74.50 million the same period last year.

NODK

NI Holdings Q1 EPS $0.31 Up From $0.30 YoY, Sales $71.43M Down From $74.50M YoY

Centrus Energy Says On May 9 It Increased Max Amount Of shares To Be Sold Through ATM Program To $200,000,000 From $100,000,000

Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.76) by 71.05 percent. This is a 56.52 percent increase over losses of $(2.99) per share from the same period last year.

Earnings Misses

Sable Offshore Q1 EPS $(1.30) Misses $(0.76) Estimate

USAU

U.S. Gold Corp. Provides Recent Warrant Exercises Update; Exercised 1,864,668 Warrants For Gross Proceeds ~$7.3M

Entera Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $42.00 thousand in sales this quarter.

Earnings Beats

ENTX

Entera Bio Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $42.00K

Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) reported quarterly losses of $(0.25) per share. This is a 98.87 percent increase over losses of $(22.14) per share from the same period last year.

ALLR

Allarity Therapeutics Q1 EPS $(0.25) Up From $(22.14) YoY

Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) reported quarterly losses of $(0.23) per share. This is a 66.67 percent increase over losses of $(0.69) per share from the same period last year.

ATHA

Athira Pharma Q1 EPS $(0.23) Up From $(0.69) YoY

Gualberto Hernandez to be appointed as CFO; Michael McCleary to Retire
SAN DIEGO, May 9, 2025 /PRNewswire/ -- PriceSmart, Inc. ("PriceSmart" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) today announced the appointment of Gualberto Hernandez as Executive Vice President and Chief Financial Officer effective June 1, 2025. PriceSmart's current Executive Vice President and Chief Financial Officer Michael McCleary resigned by mutual agreement with the Company, but will continue to serve as an Executive Vice President of the Company through September 30, 2025. Thereafter, Mr.&nbsp;McCleary has agreed to provide consulting support of up to 40 hours per month for three months following his resignation.

Management

PSMT

PriceSmart Appoints Gualberto Hernandez As Executive Vice President And CFO, Effective June 1, 2025; Michael McCleary To Retire

Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) reported quarterly losses of $(7.43) per share which missed the analyst consensus estimate of $(1.78) by 317.42 percent. This is a 75.24 percent decrease over losses of $(4.24) per share from the same period last year.

SRZN

Surrozen Q1 EPS $(7.43) Misses $(1.78) Estimate

Although financial services giant Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) technically represents one of the strongest names in the market on a year-to-date basis, V stock hasn't made progress since the end of February. Due to <a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">uncertainties surrounding the consumer economy</a>, the equity is stuck in a holding pattern. Nevertheless, the forward-looking nature of the market suggests that the payment card company may offer the bulls an upside prospect.
Granted, on paper, circumstances don't look great for V stock. It's not just about consumer sentiment levels plunging to multi-year lows. On the front lines of the economy, consumers are increasingly opening their wallets to <a href="https://www.benzinga.com/news/25/04/44916124/frozen-pizza-sales-surge-like-2009-recession-as-americans-cut-back-on-dining-out-amid-economic-strain">purchase comfort foods</a>. In particular, frozen pizza sales have experienced a significant surge, which some experts believe represents a shift in consumer behavior.
While Visa should theoretically benefit from these purchases, with the consumer pivoting away from high dollar and high-margin products, the financial impact will likely also drag the payment card company.
Among the critical drivers of the economic anxiety are the tariffs. With President Donald Trump taking a direct approach to settling disagreements with key economic partners, the sharp contrast to the Biden administration has exacerbated fears tied to inflation and other chronic post-pandemic issues.
At the same time, bullish investors have reason to be hopeful in V stock. Recently, the U.S. and China agreed to <a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">high-level trade talks</a>, which suggests some momentum toward a deal. On a broadly related note, the Trump administration <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">signed its first major trade agreement</a> with the United Kingdom, signaling progress.
Since the market doesn't trade looking through the rearview mirror, Visa could be an intriguing idea with contrarian undertones.
<h2 class="wp-block-heading">Why V Stock Could Break Out of Its Consolidation Pattern</h2>
As a blue-chip stalwart, Visa generally enjoys the benefit of the doubt. On any given moment, the chances that a one-week long position will be profitable is approximately 55%. That's not the biggest edge in the world but at scale, bullish speculation on V should theoretically end up being more profitable than not (assuming rational money management).
Still, it should be noted that the 55% figure stems from the entire distribution of sentiment regimes. Of course, that's not how capital markets operate. Instead, investors are thrown into a wild mix of fear and greed cycles. In particular cycles, the probabilities of upside can sometimes shift dramatically from the baseline.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-1024x599.jpg" alt="" class="wp-image-910704" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-1024x599.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-300x176.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-768x449.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart.jpg 1027w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure>
From a technical perspective, V stock doesn't look particularly inviting, either from a bullish or bearish angle. But from a quantitative perspective, the equity is currently printing a "6-4" sequence: six weeks of upside interspersed with four weeks of downside, with a net negative trajectory from the beginning of the period to the end.
Unlike standard technical analysis, where the practitioner must decipher a shape, pattern or other meaning from a scalar signal (such as moving averages), the 6-4 sequence is falsifiable. And if something is falsifiable, it can be categorized, quantified and deployed for probabilistic analysis.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-910708" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Empirically, the 6-4 sequence with a net negative trajectory has flashed 16 times over the past decade. In 75% of cases, the following week's price action rises, thus incentivizing a bullish outlook. Should the positive pathway continue to dominate, investors may expect a potentially "peaky" rise to around $363 over the next 10 weeks. Should the bears take control, the downside target is around $344.
<h2 class="wp-block-heading">Using the Leverage of Options for a Big Payout</h2>
To be sure, a 3% lift in V stock isn't anything to write home about — but that only applies if acquiring shares in the open market. By using the leverage of options, speculators can take this small potential uptick and translate it into a much bigger payout.
A compelling idea to consider is the 355/360 bull call spread expiring May 30. This transaction involves buying the $355 call and simultaneously selling the $360 call, for a net debit paid of $235. Should V stock rise through the short strike price of $265, the maximum reward stands at $265, a payout of nearly 113%.
Why this idea is attractive centers on the response to the 6-4 sequence. Again, if the bulls take control of the wheel, V stock may rise above $361, which would be more than enough to trigger the max payout at expiration. However, the exact timing of price action will always be a crapshoot. Therefore, the May 30 expiration date provides some time buffer for the trade to materialize.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/05/45268035/cnk-stock-short-squeeze-fervor-fade-bear-put-spread">Options Corner: Cinemark&#8217;s Short Squeeze Won&#8217;t Prevent The Credits From Eventually Rolling</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

Options Corner: Visa Flashes Potential Rebound Signal Amid Thawing Trade War Tensions

Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 11.54 percent decrease over earnings of $0.26 per share from the same period last year. The company reported $744.07 million in sales this quarter. This is a 6.05 percent decrease over sales of $792.01 million the same period last year.

Hawaiian Electric Indus Q1 Adj. EPS $0.23, Inline, Sales $744.07M Down From $792.01M YoY

HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate HF Foods Group to report an earnings per share (EPS) of $0.13.
HF Foods Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at HF Foods Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>-0.07</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>28.999999999999996%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of HF Foods Group's Stock</h3>
Shares of HF Foods Group were trading at $3.9 as of May 08. Over the last 52-week period, shares are up 43.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HFFG/earnings">To track all earnings releases for HF Foods Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HFFG

A Look Ahead: HF Foods Group's Earnings Forecast

Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) today announced that its board of directors declared a quarterly cash dividend of 67 cents per share of common stock, which reflects the company's earnings growth and strong cash generation. The dividend is payable on June 30, 2025, to shareholders of record as of the close of business on May 23, 2025.

Dividends

Marriott International Raises Quarterly Cash Dividend From $0.63 To $0.67 Per Share

FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate FiscalNote Holdings to report an earnings per share (EPS) of $-0.04.
Investors in FiscalNote Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.06, which was followed by a 4.38% drop in the share price the next day.
Here's a look at FiscalNote Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.10</td>
<td>0.01</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746821195_0.png" alt="eps graph" />
<h3>Market Performance of FiscalNote Holdings's Stock</h3>
Shares of FiscalNote Holdings were trading at $0.6437 as of May 08. Over the last 52-week period, shares are down 55.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Insights Shared by Analysts on FiscalNote Holdings</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding FiscalNote Holdings.
With 5 analyst ratings, FiscalNote Holdings has a consensus rating of Buy. The average one-year price target is $2.7, indicating a potential 319.45% upside.
<h3>Comparing Ratings with Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and RCM Technologies, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for RCM Technologies, with an average 1-year price target of $30.0, suggesting a potential 4560.56% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and RCM Technologies, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FiscalNote Holdings</td>
<td>Buy</td>
<td>-14.00%</td>
<td>$19.40M</td>
<td>-13.63%</td>
</tr>
<tr>
<td>RCM Technologies</td>
<td>Buy</td>
<td>8.28%</td>
<td>$21.57M</td>
<td>9.03%</td>
</tr>
</tbody>
</table>

Key Takeaway:
FiscalNote Holdings ranks lower in Revenue Growth compared to its peers. It also lags behind in Gross Profit margin. However, it outperforms in Consensus rating and Return on Equity.
<h3>All You Need to Know About FiscalNote Holdings</h3>
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
<h3>FiscalNote Holdings: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: FiscalNote Holdings's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -14.0%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -45.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): FiscalNote Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): FiscalNote Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: FiscalNote Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 1.77. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/NOTE/earnings">To track all earnings releases for FiscalNote Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NOTE

A Peek at FiscalNote Holdings's Future Earnings

On May 5, 2025, the Audit Committee (the "Audit Committee") of the Board of Directors of Digital Ally, Inc. (the "Company") approved the dismissal of RBSM LLP ("RBSM") as the Company's independent registered public accounting firm.
&nbsp;
The reports of RBSM on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that RBSM's reports on the consolidated financial statements of the Company as of and for the years December 31, 2024 contained an explanatory paragraph stating that "The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred substantial operating losses and will require additional capital to continue as a going concern. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty."
&nbsp;
During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with RBSM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of RBSM would have caused RBSM to make reference thereto in its reports on the consolidated financial statements for such years. During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K).
&nbsp;
The Company provided RBSM with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that RBSM to furnish the Company with a copy of its letter addressed to the Securities and Exchange Commission (the "SEC"), pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not RBSM agrees with the statements related to them made by the Company in this report. A copy of RBSM's letter to the SEC dated May 7, 2025 is attached as Exhibit 16.1 to this report.
&nbsp;
(b) Appointment of New Independent Registered Public Accounting Firm
&nbsp;
On May 5, 2025, the Audit Committee approved the appointment of Victor Mokuolu CPA PLLC ("Mokuolu") as the Company's new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal year ending December 31, 2025. During the fiscal years ended December 31, 2024 and 2023 and through May 5, 2025, neither the Company, nor anyone on its behalf, consulted Mokuolu regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and no written report or oral advice was provided to the Company by Mokuolu that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a "disagreement" (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a "reportable event" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

DGLY

Digital Ally Replaces Auditor RBSM With Victor Mokuolu CPA Despite No Disputes, Amid Going Concern Warning

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.10. 
The market awaits FibroGen's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 21.8% drop in the share price on the subsequent day.
Here's a look at FibroGen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.30</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-22.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746821173_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of FibroGen were trading at $0.3194 as of May 08. Over the last 52-week period, shares are down 74.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FGEN/earnings">To track all earnings releases for FibroGen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FGEN

A Preview Of FibroGen's Earnings

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Comments

Kezar Life Sciences

Noticias

Últimas noticias sobre Kezar Life Sciences (NASDAQ:KZR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL